• 1
    Berek JS, Friedlander ML, Bast RC Jr. Ovarian cancer. In: Hong WK, Bast RC Jr, Hait W, et al, eds. Holland-Frei Cancer Medicine. 8th ed. American Association for Cancer Research. Shelton CT: People's Medical Publishing House-USA; 2010: 1344-1375.
  • 2
    Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin. 2009; 59: 225-249.
  • 3
    Bast RC Jr, Hennessy B, Mills GB. The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer. 2009; 9: 415-428.
  • 4
    Baylin SB, Ohm JE. Epigenetic gene silencing in cancer—a mechanism for early oncogenic pathway addiction? Nat Rev Cancer. 2006; 6: 107-116.
  • 5
    Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet. 2002; 3: 415-428.
  • 6
    Issa JP. DNA methylation as a therapeutic target in cancer. Clin Cancer Res. 2007; 13: 1634-1637.
  • 7
    Santos FP, Kantarjian H, Garcia-Manero G, Issa JP, Ravandi F. Decitabine in the treatment of myelodysplastic syndrome. Expert Rev Anticancer Ther. 2010; 10: 9-22.
  • 8
    Fu S, Hu W, Iyer R, et al. A phase IB-IIA study to reverse platinum resistance by use of a hypomethylating agent azacitidine in platinum-resistant or refractory epithelial ovarian Cancer. In press.
  • 9
    Dokmanovic M, Clarke C, Marks PA. Histone deacetylase inhibitors: overview and perspectives. Mol Cancer Res. 2007; 5: 981-989.
  • 10
    Zhang C, Richon V, Ni X, Talpur R, Duvic M. Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action. J Invest Dermatol. 2005; 125: 1045-1052.
  • 11
    Modesitt SC, Sill M, Hoffman JS, Bender DP. A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2008; 109: 182-186.
  • 12
    Piekarz RL, Sackett DL, Bates SE. Histone deacetylase inhibitors of demethylating agents: clinical development of histone deacetylase inhibitors for cancer therapy. Cancer J. 2007; 13: 30-39.
  • 13
    Garcia-Manero G, Kantarjian HM, Sanchez-Gonzolez B, et al. Phase 1/2 study of the combination of 5-aza-2′-deoxycytidine with valproic acid in patients with leukemia. Blood. 2006; 108: 3271-3279.
  • 14
    Lu KH, Patterson AP, Wang L, et al. Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. Clinical Cancer Res. 2004; 10: 3291-3300.
  • 15
    Rosen DG, Wang L, Jain AJ, et al. Expression of the tumor suppressor gene ARHI in epithelial ovarian cancer is associated with increased expression of p21WAF1/CIP1 and prolonged progression-free survival. Clin Cancer Res. 2004; 10: 6559-6566.
  • 16
    Feng W, Marquez RT, Lu Z, et al. Imprinted tumor suppressor genes ARHI and PEG3 are the most frequently down-regulated in human ovarian cancers by loss of heterozygosity and promoter mehtylation. Cancer. 2008; 112: 1489-1502.
  • 17
    Lu Z, Luo RZ, Peng H, et al. Transcriptional and posttranscriptional down-regulation of the imprinted tumor suppressor gene ARHI (DRAS3) in ovarian cancer. Clin Cancer Res. 2006; 12: 2404-2413.
  • 18
    Fujii S, Luo RZ, Yuan J, et al. Reactivation of the silenced and imprinted alleles of ARHI is associated with increased histone H3 acetylation and decreased histone H3 lysine 9 methylation. Hum Mol Genet. 2003; 12: 1791-1800.
  • 19
    Lu Z, Luo RZ, Lu Y, et al. A Ras-related imprinted tumor suppressor gene ARHI regulates autophagy and tumor dormancy in ovarian cancer. J Clin Invest. 2008; 118: 3917-3929.
  • 20
    Levine B. Eating oneself and uninvited guests: autophagy-related pathways in cellular defense. Cell. 2005; 120: 159-162.
  • 21
    Gediya LK, Chopra P, Purushottamachar P, Maheshwari N, Njar VC. A new simple and high-yield synthesis of suberoylanilide hydroxamic acid and its inhibitory effect alone or in combination with retinoids on proliferation of human prostate cancer cells. J Med Chem. 2005; 48: 5047-5051.
  • 22
    Lee JJ, Kong M, Ayers GD, Lotan R. SYNERGY Software. Accessed on September 1, 2010.
  • 23
    Chou TC. The median-effect principle and the combination index for quantification of synergism and antagonism. In: Chou TC, Rideout DC, eds. Synergism and Antagonism in Chemotherapy. San Diego, CA: Academic Press; 1991: 61-101.
  • 24
    Mantel N. Evaluation of survival data and 2 new rank order statistics arising in its consideration. Cancer Chemotherapy Rep. 1966; 50: 163-170.
  • 25
    Efron B. The efficiency of Cox's likelihood function for censored data. JASA. 1977; 72: 557-565.
  • 26
    Chou TC. Theoretical basis, experimental design, and computerized simulation and antagonism in drug combination studies. Pharmacol Rev. 2006; 58: 621-681.
  • 27
    Yang H, Hoshino K, Sanchez-Gonzolez B, Kantarjian H, Garcia-Manero G. Antileukemia activity of the combination of 5-aza-2′-deoxycytidine with valproic acid. Leuk Res. 2005; 29: 739-748.
  • 28
    Hurtubise A, Momparler RL. Effect of histone deacetylase inhibitor LAQ824 on antineoplastic action of 5-aza-2′-deoxycytidine on human breast carcinoma cells. Cancer Chemother Pharmacol. 2006; 58: 618-625.
  • 29
    Fandy TE, Carraway H, Gore SD. DNA demethylating agents and histone deacetylase inhibitors in hematologic malignancies. Cancer J. 2007; 13: 40-48.
  • 30
    Venturelli S, Armeanu S, Pathil A, et al. Epigenetic combination therapy as a tumor-selective treatment approach for hepatocellular carcinoma. Cancer. 2007; 109: 2132-2141.
  • 31
    Li Y, Hu W, Shen DY, Kavanagh JJ, Fu S. Azacitidine enhances sensitivity of platinum-resistant ovarian cancer cells to carboplatin through induction of apoptosis. Am J Obstet Gynecol. 2009; 200: 177.e1-177.e9.
  • 32
    Sonnemann J, Gange J, Pitz S, et al. Comparative evaluation of the treatment efficacy of suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer cell lines and primary ovarian cancer cells from patients [serial online]. BMC Cancer. 2006; 6: 183.
  • 33
    Dietrich CS, 3rd, Greenberg VL, DeSimone CP, et al. Suberoylanilide hydroxamic acid (SAHA) potentiates paclitaxel-induced apoptosis in ovarian cancer cell lines. Gynecol Oncol. 2010; 116: 126-130.
  • 34
    Steele N, Finn P, Brown R, Plumb JA. Combined inhibition of DNA methylation and histone acetylation enhances gene re-expression and drug sensitivity in vivo. Br J Cancer. 2009; 100: 758-763.
  • 35
    Cashen AF, Shah AK, Todt L, Fisher N, DiPeriso J. Pharmacokinetics of decitabine administered as a 3-hour infusion to patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Cancer Chemother Pharmacol. 2008; 61: 759-766.
  • 36
    Wijermans P, Lubbert M, Verhoef G, et al. Low-dose 5-aza-2′-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. J Clin Oncol. 2000; 18: 956-962.
  • 37
    Issa JP, Gharibyan V, Cortes J, et al. Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate. J Clin Oncol. 2005; 23: 3948-3956.
  • 38
    Menendez L, Walker D, Matyunia LV, et al. Identification of candidate methylation-responsive genes in ovarian cancer [serial online]. Mol Cancer. 2007; 6: 10.
  • 39
    Adair SJ, Hogan KT. Treatment of ovarian cancer cell lines with 5-aza-2 deoxycytidine up-regulates the expression of cancer-testis antigens and class I major histocompatibility complex-encoded molecules. Cancer Immunol. 2009; 58: 589-601.
  • 40
    Leshchenko VV, Kuo P-Y, Shaknovich R, et al. Genomewide DNA methylation analysis reveals novel targets for drug development in mantel cell lymphoma. Blood. 2010; 116: 1025-1034.